Bristol Myers Squibb Presents Positive Phase 3 Trial Results

Pharmaceutical company reports efficacy and safety of new heart disease treatment.

Mar. 29, 2026 at 5:52pm

Got story updates? Submit your updates here. ›

Bristol Myers Squibb, a major pharmaceutical company, has announced positive results from its Phase 3 SCOUT-HCM clinical trial, demonstrating the efficacy and safety of a new treatment for hypertrophic cardiomyopathy (HCM), a serious and progressive heart disease.

Why it matters

HCM is a leading cause of sudden cardiac death in young athletes and can severely impact quality of life. The positive trial results could pave the way for a new treatment option for patients living with this debilitating condition.

The details

The SCOUT-HCM trial evaluated the safety and efficacy of Bristol Myers Squibb's investigational drug in patients with symptomatic obstructive HCM. The study found the treatment significantly improved patient symptoms and heart function compared to a placebo.

  • The Phase 3 SCOUT-HCM trial was conducted over a 24-month period.
  • Bristol Myers Squibb presented the positive results on March 29, 2026.

The players

Bristol Myers Squibb

A major global pharmaceutical company that develops innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“These positive results from the SCOUT-HCM trial represent an important milestone in our efforts to address the significant unmet medical need for patients living with this debilitating heart disease.”

— Samit Hirawat, Chief Medical Officer, Bristol Myers Squibb

What’s next

Bristol Myers Squibb plans to submit the data to regulatory authorities for potential approval of the new HCM treatment.

The takeaway

The promising Phase 3 trial results offer hope for a new therapeutic option that could significantly improve outcomes and quality of life for patients suffering from hypertrophic cardiomyopathy, a serious and often life-threatening heart condition.